Physician profile
Swetha Boddeda
NPI 1194145185
$2,323.71
in general payments reported to CMS, 2019-2025
33 companies · $436 in 2025
The $436 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.66 · 2020: $231 · 2021: $301 · 2022: $444 · 2023: $371 · 2024: $459 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,266.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $422.76 | 2020-2025 | Skyrizi |
| Amgen INC. | $386.01 | 2020-2025 | Enbrel, Otezla, Evenity |
| Horizon Therapeutics Plc | $161.08 | 2022-2023 | Krystexxa |
| Genzyme Corporation | $141.59 | 2020-2025 | |
| Mallinckrodt Hospital Products INC. | $133.74 | 2021-2024 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $121.92 | 2020-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.50 | 2020-2025 | Ofev |
| Actelion Pharmaceuticals US, INC. | $86.40 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Lilly USA, LLC | $75.26 | 2020-2024 | Taltz, Mounjaro, Humulin |
| Eisai INC. | $54.93 | 2022 | |
| Baxter Healthcare | $49.18 | 2023 | Hillrom - Life 2000 Ventilation System |
| Ucb, INC. | $45.13 | 2019-2025 | Bimzelx |
| Glaxosmithkline, LLC. | $44.05 | 2021 | |
| Exelixis INC. | $43.48 | 2021-2023 | Cabometyx |
| Pfizer INC. | $40.27 | 2023-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.39 | 2021 | |
| Beigene USA, INC. | $29.33 | 2022-2023 | Brukinsa |
| Grifols USA, LLC | $28.05 | 2025 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $27.88 | 2022 | |
| Medtronic, INC. | $24.58 | 2025 | Minimed 780g |
| Averitas Pharma INC. | $23.73 | 2025 | Qutenza |
| Fresenius Kabi USA, LLC | $21.36 | 2025 | |
| Janssen Pharmaceuticals, INC | $19.40 | 2022 | |
| Foundation Medicine, INC. | $18.79 | 2023 | |
| Dexcom, INC. | $18.71 | 2025 | Dexcom G6 Transmitter |
| Organon LLC | $18.42 | 2025 | Hadlima, Renflexis |
| Astrazeneca Pharmaceuticals LP | $18.26 | 2025 | Saphnelo |
| Recordati_rare_diseases_inc. | $17.72 | 2023 | Panhematin |
| Ascendis Pharma Endocrinology INC | $14.95 | 2025 | Yorvipath |
| Ipsen Biopharmaceuticals, INC | $14.45 | 2022 | |
| Nevro Corp. | $14.20 | 2024 | Senza |
| Cequr Corporation | $13.36 | 2025 | Cequr Simplicity |
| Philips North America LLC | $13.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swetha Boddeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.